Compare Ascendis Pharma A/S (ASND) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Verisign, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.25 (market cap $17.74B), while Verisign, Inc. trades at $270.69 (market cap $24.58B). The key difference: Verisign, Inc. is the larger of the two by market cap, and Verisign, Inc. pays a 1.2% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | VRSN | |
|---|---|---|
Market Cap | $17.74B | $24.58B |
Sector | Health | Technology |
52-Week High | $277.18 | $310.00 |
52-Week Low | $163.32 | $211.49 |
Enterprise Value | $18.11B | $25.82B |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
VeriSign (VRSN) trades at $270.11, up 0.05% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $327.67. The company reported Q1 2026 EPS of $2.34, beating expectations, and maintains strong profitability with a net income margin near 50%. Recent news highlights AI-driven domain registration growth and the upcoming Q2 2026 earnings report on July 23, 2026.
The outlook for VRSN is positive, supported by stable revenue growth, high margins, and analyst optimism, but risks include AI disruption to its domain business, contract renewals, and a high debt load. The stock offers potential upside to the consensus target, though investors should monitor earnings execution and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
